See Editorial on Page 241
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis
Article first published online: 11 MAR 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 19, Issue 3, pages 250–258, March 2013
How to Cite
Goldberg, D. S., Camp, A., Martinez-Camacho, A., Forman, L., Fortune, B. and Reddy, K. R. (2013), Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl, 19: 250–258. doi: 10.1002/lt.23587
This work was supported by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (grant F32 1-F32-DK-089694-01 to David S. Goldberg).
- Issue published online: 11 MAR 2013
- Article first published online: 11 MAR 2013
- Accepted manuscript online: 5 DEC 2012 02:43AM EST
- Manuscript Accepted: 18 NOV 2012
- Manuscript Received: 13 SEP 2012
Patients with primary sclerosing cholangitis (PSC) are at increased risk for bacterial cholangitis because of biliary strictures and bile stasis. A subset of PSC patients suffer from repeated episodes of bacterial cholangitis, which can lead to frequent hospitalizations and impaired quality of life. Although waitlist candidates with PSC and bacterial cholangitis frequently receive exception points and/or are referred for living donor transplantation, the impact of bacterial cholangitis on waitlist mortality is unknown. We performed a retrospective cohort study of all adult waitlist candidates with PSC who were listed for initial transplantation between February 27, 2002 and June 1, 2012 at the University of Pennsylvania and the University of Colorado–Denver. During this period, 171 PSC patients were waitlisted for initial transplantation. Before waitlisting, 38.6% (66/171) of the patients had a history of bacterial cholangitis, whereas 28.0% (44/157) of the patients with at least 1 Model for End-Stage Liver Disease update experienced cholangitis on the waitlist. During follow-up, 30 patients (17.5%) were removed from the waitlist for death or clinical deterioration, with 46.7% (14/30) developing cholangiocarcinoma. Overall, 12 of the 82 waitlist candidates (14.6%) who ever had an episode of cholangitis were removed for death or clinical deterioration, whereas 18 of the 89 candidates (20.2%) without cholangitis were removed (P = 0.34 for a comparison of the 2 groups). No patients were removed because of bacterial cholangitis. In multivariate competing-risk models, a history of bacterial cholangitis was not associated with an increased risk of waitlist removal for death or clinical deterioration (subhazard ratio = 0.67, 95% confidence interval = 0.65–0.70, P < 0.001). In summary, waitlist transplant candidates with PSC and bacterial cholangitis do not have an increased risk of waitlist mortality. The data call into question the systematic granting of exception points or referral for living donor transplantation due to a perceived risk of increased waitlist mortality. Liver Transpl 19:250–258, 2013. © 2013 AASLD.